Logo

People in the News: Gustavo Salem, Michael Liang, Charles Wagner

May 03, 2014
Premium

SISCAPA Assay Technologies has appoint Gustavo Salem president and CEO.

Salem was previously an SAT board member. Prior to that he was VP and general manager of the Biological Systems Division at Agilent as well as president and CEO of Assay Designs.

Baird Capital partner Michael Liang has joined Integrated Diagnostics' board of directors as part of the company's recent $30 million Series B funding round.

Good Start Genetics has appointed Charles Wagner to its board of directors. Wagner is currently CFO and executive vice president of finance and administration of Bruker Corporation.

Filed under

Proteomics & Protein Research
proteomics
Integrated Diagnostics
SISCAPA Assay Technologies
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.